Prognostic Understanding and Quality of Life in Patients With Advanced Lung Cancer: A Multicenter Study.


Journal

Clinical lung cancer
ISSN: 1938-0690
Titre abrégé: Clin Lung Cancer
Pays: United States
ID NLM: 100893225

Informations de publication

Date de publication:
05 2019
Historique:
received: 29 06 2018
revised: 09 11 2018
accepted: 23 11 2018
pubmed: 13 1 2019
medline: 4 4 2020
entrez: 13 1 2019
Statut: ppublish

Résumé

Communication about the palliative setting remains a barrier for many physicians because they are afraid to harm the patient by giving bad news. We sought to determine whether this a valid concern; the influence of prognostic understanding on patients' quality of life (QoL); and which factors influence this relationship. The present multicenter, cross-sectional study used a questionnaire to measure patients' prognostic understanding, QoL, mood, and coping strategy. We surveyed 125 patients with advanced lung cancer. Prognostic understanding correlated significantly with emotional well-being (r = -0.20; P = .01) and pain (r = 0.43; P = .00) but not with anxiety (r = 0.12, P = .12) or depression (r = 0.05; P = .29). Patients with anxiety (r = -0.23; P = .01) and patients with depressive feelings (r = -0.63; P = .00) experienced poorer QoL. Four in 10 patients reported feelings of anxiety and/or depression. Positive reframing as a coping strategy was associated with a better QoL (r = 0.25; P = .00). Prognostic understanding was related to poorer emotional well-being and more pain but does not affect mood. Four in 10 patients reported feelings of anxiety and/or depression, which were associated with a poorer QoL. A holistic approach seems necessary when physicians communicate about the palliative setting.

Identifiants

pubmed: 30635259
pii: S1525-7304(18)30307-3
doi: 10.1016/j.cllc.2018.11.011
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e369-e375

Informations de copyright

Copyright © 2018 Elsevier Inc. All rights reserved.

Auteurs

Annelies Janssens (A)

Multidisciplinary Oncology Center Antwerp, Antwerp Hospital University, Edegem, Belgium. Electronic address: annelies.janssens@uza.be.

Sofia Derijcke (S)

Department of Pulmonology-Thoracic Oncology, AZ Groeninge, Kortrijk, Belgium.

Daniëlle Galdermans (D)

Department of Pulmonology-Thoracic Oncology, ZNA Middelheim, Antwerp, Belgium.

Marc Daenen (M)

Department of Pulmonology, Ziekenhuis Oost Limburg, Genk, Belgium.

Veerle Surmont (V)

Department of Pulmonology-Thoracic Oncology, Ghent University, Ghent, Belgium.

Els De Droogh (E)

Department of Pulmonology-Thoracic Oncology, ZNA Middelheim, Antwerp, Belgium.

Anneke Lefebure (A)

Department of Pulmonology-Thoracic Oncology, ZNA STER, Antwerp, Belgium.

Erika Saenen (E)

Department of Lung Diseases/Allergology, AZ Heilige Familie, Reet, Belgium.

Elke Vandenbroucke (E)

Department of Pulmonology-Thoracic Oncology, AZ Monica, Antwerp, Belgium.

Ann-Marie Morel (AM)

Department of Pulmonology, Sint-Jozefkliniek Bornem and Willebroek, Bornem, Belgium.

Anna Sadowska (A)

Department of Pulmonology, Ziekenhuis Maas en Kempen, Campus Maaseik, Maaseik, Belgium.

Jan P van Meerbeeck (JP)

Multidisciplinary Oncology Center Antwerp, Antwerp Hospital University, Edegem, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH